<DOC>
	<DOC>NCT00842023</DOC>
	<brief_summary>The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.</brief_summary>
	<brief_title>Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy</brief_title>
	<detailed_description>No additional details provided</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardio-Renal Syndrome</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<mesh_term>Natriuretic Peptide, Brain</mesh_term>
	<criteria>At least 18 years of age. Subject must be able to understand the potential risks and benefits associated with the study. Baseline systolic blood pressure â‰¥ 90 mm Hg at the time of enrollment. Clinical symptoms of dyspnea and laboratory admission BNP levels &gt; 500 pg/mL. Neither pregnant or breastfeeding at the time of enrollment. Authorization of patient's enrollment by patient's medical provider. &lt;18 years of age Denies written informed consent Pregnant or lactating. Baseline systolic BP &lt; 90 mmHg or cardiogenic shock No symptoms of congestion or admission BNP &lt; 500 pg/mL Known allergy to E.coliderived products, or any history of anaphylactic reactions to nesiritide. Receiving dialysis at the time of enrollment. Serum creatinine &gt; 2.5 mg/dL at the time of enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Natriuretic peptides</keyword>
	<keyword>BNP</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Nitoglycerin</keyword>
	<keyword>Biomarkers</keyword>
</DOC>